
Supplementary Table 1. General questionnaire, breast cancer module and elderly cancer questionnaire

General EORTC questionnaire

QLQ-C30

Functional scales (1)	Physical, role, cognitive, emotional, social, global quality of life.
-----------------------	---

Symptom scales and/or items (2)	Fatigue, nausea and vomiting, pain. Individual items on dyspnoea, sleep disturbance, appetite loss, constipation, diarrhoea, financial impact.
---------------------------------	--

EORTC module QLQ-BR42

Functioning scales and/or items (1)	Body image, sexual functioning, breast satisfaction. Individual items on sexual enjoyment, future perspective.
-------------------------------------	--

Symptoms scales and/or items (2)	Systemic chemotherapy side effects, arm symptoms, breast symptoms, endocrine-related symptoms, vaginal symptoms, hand/feet symptoms/neuropathy, weight gain, musculoskeletal symptoms, skin toxicity/neuropathy (59-62).
----------------------------------	--

EORTC questionnaire elderly

cancer patients QLQ-ELD14

Functioning scale and item (1)	Maintaining purpose, item on family support.
--------------------------------	--

Symptoms scales and/or items (2)	Mobility, worries about others, future worries, burden of illness. Item on joint stiffness.
----------------------------------	---

-
1. Scores range from 0 to 100, with higher scores representing higher functional levels.
 2. Scores range from 0 to 100, with higher scores representing greater degrees of symptoms.

Supplementary table S2a. Group comparisons: QLQ-C30. Adjusted for time since beginning of treatment

	Physical Functioning	Role Functioning	Emotional Functioning	Cognitive Functioning	Social Functioning	Global Health Status
Age at treatment						
< 55 years	89.3 (11.5)	96.3 (10.2)	76.6 (22.1)	90.2 (16.2)	97.6 (8.0)	81.3 (14.2)
55–59	81.2 (17.8)	91.9 (17.3)	78.7 (24.2)	88.5 (14.6)	96.3 (12.3)	75.7 (14.2)
60–69	82.9 (18.3)	91.9 (16.2)	75.5 (19.8)	89.7 (13.9)	96.4 (10.6)	75.0 (20.0)
70 or more	80.1 (15.5)	91.8 (13.4)	78.2 (19.4)	86.1 (13.8)	96.5 (9.4)	71.5 (15.6)
p-value (bivariate)	0.045	0.378	0.722	0.324	0.931	0.052
Adjusted p-value	0.037	0.545	0.844	0.006	0.128	0.226
Cohabitation						
Alone	83.5 (16.0)	94.5 (11.9)	79.1 (18.1)	89.0 (13.5)	97.1 (10.3)	74.7 (16.7)
With a partner	84.8 (16.0)	93.1 (14.9)	75.4 (20.0)	89.8 (14.0)	96.7 (10.1)	75.2 (18.7)
Children over 18 years old	69.7 (18.5)	78.8 (18.4)	72.0 (18.4)	80.3 (16.4)	87.9 (15.1)	65.2 (18.6)
With other people	75.2 (17.7)	90.5 (14.5)	82.9 (17.6)	84.9 (12.8)	100.0 (0.0)	76.2 (19.6)
p-value (bivariate)	0.003	0.006	0.181	0.086	0.013	0.349
Adjusted p-value	0.298	0.287	0.282	0.142	0.116	0.239
Breast surgery						
Conservative	82.6 (18.3)	91.3 (16.8)	76.2 (21.1)	89.6 (14.7)	95.5 (11.8)	74.9 (18.6)
Radical	83.4 (14.9)	94.4 (12.0)	77.3 (19.9)	87.5 (13.7)	98.1 (7.1)	75.6 (16.7)
p-value (bivariate)	0.663	0.078	0.642	0.200	0.030	0.722
Adjusted p-value	0.268	0.404	0.801	0.345	0.187	0.119
Axillary surgery						
Axillary node dissection	82.3 (16.2)	92.5 (14.5)	76.1 (20.4)	89.8 (12.7)	96.2 (11.2)	74.3 (15.3)
Sentinel node biopsy	83.4 (17.9)	92.3 (15.9)	76.5 (20.6)	87.9 (15.4)	96.7 (9.9)	75.5 (19.3)
No	80.4 (13.0)	94.1 (11.7)	81.4 (23.9)	91.2 (12.0)	97.1 (8.8)	75.0 (18.2)
p-value (bivariate)	0.706	0.894	0.617	0.423	0.919	0.852
Adjusted p-value	0.224	0.261	0.844	0.058	0.151	0.054
Radiotherapy						
No	83.5 (17.9)	95.7 (10.1)	79.1 (21.1)	85.1 (13.6)	98.2 (7.2)	78.4 (19.2)
Yes	82.7 (16.9)	92.0 (15.8)	76.2 (20.6)	89.3 (14.4)	96.3 (10.8)	74.7 (17.4)
p-value (bivariate)	0.766	0.120	0.380	0.064	0.235	0.190
Adjusted p-value	0.169	0.275	0.821	0.251	0.101	0.149
Limiting comorbidity						
No	87.9 (14.0)	95.6 (11.8)	78.4 (20.9)	91.1 (13.3)	98.5 (7.0)	80.4 (16.3)
Yes	77.0 (18.3)	88.8 (17.6)	74.7 (20.3)	86.2 (15.0)	94.3 (12.8)	69.1 (17.7)
p-value (bivariate)	0.000	0.000	0.115	0.002	0.000	0.000
Adjusted p-value	0.191	0.299	0.819	0.244	0.112	0.160

Adjusted p-value: adjusting for years since beginning of treatment.

Supplementary table S2b. Group comparisons: QLQ-C30. Adjusted for time since beginning of treatment.

	Fatigue	Nausea	Pain	Dyspnoea	Insomnia	Appetite loss
Age at treatment						
< 55 years	13.8 (13.3)	0.8 (5.2)	15.0 (18.6)	16.3 (23.7)	25.2 (32.3)	2.4 (11.5)
55–59	17.8 (20.8)	2.2 (11.0)	23.3 (27.2)	3.7 (10.6)	17.0 (23.2)	3.0 (11.9)
60–69	23.1 (22.4)	0.2 (1.8)	22.8 (21.9)	6.3 (14.6)	23.5 (28.4)	4.9 (14.0)
70 or more	21.9 (17.6)	3.0 (17.1)	21.4 (19.2)	10.9 (22.0)	29.4 (30.4)	8.5 (22.0)
p-value (bivariate)	0.045	0.170	0.215	0.002	0.168	0.159
Adjusted p-value	0.076	0.095	0.235	0.132	0.635	0.921
Cohabitation						
Alone	20.1 (20.9)	2.4 (15.2)	20.2 (20.7)	9.4 (20.3)	20.8 (26.2)	7.1 (18.6)
With a partner	21.2 (21.1)	1.1 (6.7)	20.6 (21.9)	6.6 (14.8)	22.5 (29.8)	3.2 (11.8)
Children over 18 years old	36.4 (16.5)	0.0 (0.0)	24.2 (24.0)	15.2 (22.9)	36.4 (18.0)	9.1 (21.6)
With other people	21.7 (22.4)	0.0 (0.0)	30.2 (20.2)	7.9 (14.5)	20.6 (22.3)	7.9 (14.5)
p-value (bivariate)	0.119	0.661	0.246	0.311	0.372	0.134
Adjusted p-value	0.413	0.130	0.340	0.025	0.946	0.899
Breast surgery						
Conservative	20.8 (21.8)	1.7 (11.5)	22.0 (22.9)	8.7 (18.6)	23.9 (28.9)	5.6 (16.9)
Radical	21.0 (18.3)	0.4 (3.3)	20.8 (20.3)	7.5 (16.4)	24.2 (28.9)	4.3 (13.4)
p-value (bivariate)	0.952	0.240	0.648	0.558	0.932	0.476
Adjusted p-value	0.181	0.130	0.206	0.019	0.947	0.808
Axillary surgery						
Axillary node dissection	19.8 (19.0)	0.6 (4.5)	20.7 (21.6)	9.9 (17.7)	24.6 (26.5)	4.8 (14.1)
Sentinel node biopsy	21.4 (21.5)	1.6 (11.5)	21.8 (22.2)	7.2 (17.9)	23.3 (30.1)	4.8 (16.5)
No	22.9 (18.2)	0.0 (0.0)	25.5 (21.3)	9.8 (15.7)	29.4 (30.9)	9.8 (15.7)
p-value (bivariate)	0.743	0.573	0.696	0.409	0.687	0.443
Adjusted p-value	0.175	0.110	0.184	0.030	0.956	0.665
Radiotherapy						
No	17.3 (20.7)	0.4 (2.4)	21.6 (23.0)	7.8 (14.3)	23.4 (34.0)	2.8 (9.4)
Yes	21.5 (20.4)	1.3 (10.0)	21.6 (21.7)	7.9 (17.7)	24.0 (27.9)	5.5 (16.5)
p-value (bivariate)	0.191	0.512	0.999	0.964	0.892	0.277
Adjusted p-value	0.257	0.107	0.127	0.017	0.943	0.812
Limiting comorbidity						
No	14.2 (15.2)	1.5 (9.9)	17.0 (20.0)	7.3 (16.4)	19.4 (26.3)	3.5 (13.1)
Yes	28.7 (22.9)	0.8 (8.4)	26.9 (22.8)	9.4 (19.1)	29.5 (30.7)	6.8 (17.9)
p-value (bivariate)	0.000	0.520	0.000	0.292	0.002	0.059
Adjusted p-value	0.274	0.092	0.259	0.021	0.905	0.800

Adjusted p-value: adjusting for years since beginning of treatment.

Supplementary table S2c. Group comparisons: QLQ-C30. Adjusted for time since beginning of treatment.

	Constipation	Diarrhoea	Financial difficulties	Sum score C30
Age at treatment				
< 55 years	10.6 (20.3)	2.4 (11.5)	4.9 (21.8)	89.5 (7.3)
55–59	6.8 (15.4)	1.5 (9.9)	3.0 (15.6)	89.2 (10.1)
60–69	6.3 (18.0)	2.2 (11.2)	1.4 (10.0)	88.2 (9.4)
70 or more	13.9 (25.4)	3.0 (11.2)	3.0 (17.1)	86.2 (10.6)
p-value (bivariate)	0.053	0.916	0.552	0.255
Adjusted p-value	0.130	0.899	0.525	0.263
Cohabitation				
Alone	10.2 (21.8)	3.9 (14.0)	1.6 (11.4)	88.4 (10.7)
With a partner	7.3 (18.7)	1.1 (7.9)	2.1 (12.9)	88.9 (9.2)
Children over 18 years old	12.1 (22.5)	9.1 (21.6)	18.2 (40.5)	80.5 (10.5)
With other people	11.1 (24.3)	0.0 (0.0)	4.8 (21.8)	87.2 (6.7)
p-value (bivariate)	0.605	0.026	0.007	0.045
Adjusted p-value	0.106	0.862	0.447	0.352
Breast surgery				
Conservative	11.1 (23.3)	2.3 (11.4)	1.6 (11.5)	87.6 (10.8)
Radical	4.8 (12.5)	2.4 (10.6)	3.8 (18.1)	88.9 (7.3)
p-value (bivariate)	0.007	0.906	0.190	0.248
Adjusted p-value	0.130	0.925	0.621	0.648
Axillary surgery				
Axillary node dissection	9.1 (18.6)	2.1 (10.3)	3.9 (18.9)	88.0 (8.2)
Sentinel node biopsy	8.1 (21.1)	2.5 (11.7)	1.8 (11.9)	88.2 (10.5)
No	9.8 (15.7)	2.0 (8.1)	0.0 (0.0)	87.3 (6.8)
p-value (bivariate)	0.880	0.945	0.373	0.938
Adjusted p-value	0.126	0.924	0.510	0.542
Radiotherapy				
No	4.3 (14.9)	2.1 (10.8)	5.0 (20.8)	89.4 (8.6)
Yes	9.1 (20.4)	2.4 (11.2)	1.6 (11.7)	87.9 (9.7)
p-value (bivariate)	0.121	0.882	0.118	0.328
Adjusted p-value	0.156	0.922	0.639	0.602
Limiting comorbidity				
No	8.4 (18.2)	2.4 (11.8)	1.6 (11.4)	90.6 (8.6)
Yes	8.7 (21.9)	2.3 (10.1)	3.4 (17.4)	85.1 (9.8)
p-value (bivariate)	0.893	0.955	0.256	0.000
Adjusted p-value	0.107	0.922	0.507	0.625

Adjusted p-value: adjusting for years since beginning of treatment.

Supplementary table S3a. Group comparisons: QLQ-BR42 scales. Adjusted for time since beginning of treatment.

	Body Image	Sexual Function	Sexual Enjoyment	Future Perspective	Breast Satisfaction	Arm Symptoms
Age at treatment						
< 55 years	91.7 (20.7)	12.7 (15.9)	38.1 (17.8)	73.2 (26.1)	78.7 (25.2)	8.1 (11.1)
55–59	92.2 (20.8)	12.8 (17.3)	46.2 (21.7)	69.6 (29.1)	77.0 (28.0)	11.1 (19.8)
60–69	97.0 (10.0)	12.7 (15.3)	37.9 (26.7)	75.9 (25.8)	75.2 (27.1)	9.4 (14.3)
70 or more	97.3 (8.3)	8.0 (14.5)	50.0 (18.3)	81.1 (24.8)	78.9 (20.2)	10.6 (15.0)
p-value (bivariate)	0.030	0.577	0.512	0.131	0.827	0.763
Adjusted p-value	0.596	0.013	0.646	0.401	0.040	0.301
Cohabitation						
Alone	96.7 (12.2)	5.3 (11.2)	14.3 (17.8)	80.8 (23.8)	74.0 (26.7)	9.0 (12.3)
With a partner	95.4 (13.6)	16.7 (16.2)	45.1 (21.9)	71.6 (27.5)	77.9 (25.8)	9.7 (16.2)
Children over 18 years old	95.5 (10.1)	8.3 (9.6)	0.0 (0.0)	72.7 (25.0)	85.7 (26.2)	12.1 (13.6)
With other people	99.6 (1.8)	8.3 (16.7)	11.1 (19.2)	87.3 (24.7)	71.4 (17.8)	7.9 (15.4)
p-value (bivariate)	0.516	0.019	0.000	0.011	0.476	0.878
Adjusted p-value	0.141	0.002	0.641	0.366	0.300	0.575
Breast surgery						
Conservative	95.8 (14.3)	10.3 (14.6)	37.9 (26.7)	74.2 (26.5)	76.1 (26.5)	9.8 (14.7)
Radical	95.4 (12.7)	15.9 (16.9)	43.4 (19.5)	78.2 (25.9)	77.1 (24.6)	9.6 (15.3)
p-value (bivariate)	0.809	0.019	0.309	0.186	0.766	0.915
Adjusted p-value	0.104	0.028	0.779	0.483	0.265	0.514
Axillary surgery						
Axillary node dissection	94.1 (15.5)	10.1 (15.7)	38.5 (27.8)	75.7 (26.2)	73.2 (27.0)	11.3 (15.2)
Sentinel node biopsy	96.7 (12.5)	14.6 (15.8)	42.3 (21.5)	75.7 (26.5)	78.7 (25.2)	8.8 (14.8)
No	94.1 (12.4)	2.8 (6.5)	0.0 (0.0)	80.4 (23.7)	66.7 (0.0)	9.2 (15.3)
p-value (bivariate)	0.239	0.016	0.046	0.772	0.226	0.368
Adjusted p-value	0.252	0.024	0.818	0.549	0.535	0.616
Radiotherapy						
No	95.0 (11.9)	14.4 (16.5)	36.1 (22.3)	81.6 (28.5)	77.3 (24.2)	8.7 (11.6)
Yes	95.7 (14.0)	12.0 (15.6)	40.7 (24.5)	75.0 (25.8)	76.3 (26.0)	9.9 (15.5)
p-value (bivariate)	0.752	0.506	0.542	0.115	0.844	0.642
Adjusted p-value	0.095	0.022	0.920	0.563	0.290	0.451
Limiting comorbidity						
No	96.8 (11.6)	13.9 (16.2)	38.5 (24.8)	79.7 (25.0)	77.4 (26.4)	8.0 (14.7)
Yes	94.3 (15.6)	9.3 (14.3)	43.6 (22.6)	71.2 (27.0)	75.6 (24.8)	11.7 (15.1)
p-value (bivariate)	0.109	0.048	0.376	0.004	0.618	0.029
Adjusted p-value	0.080	0.033	0.892	0.418	0.264	0.439

Adjusted p-value: adjusting for years since beginning of treatment.

Supplementary table S3b. Group comparisons: QLQ-BR42 scales. Adjusted for time since beginning of treatment.

	Breast Symptoms	Systemic Chemotherapy Side Effects	Vaginal Symptoms
Age at treatment			
< 55 years	4.9 (8.1)	15.0 (10.8)	5.6 (10.8)
55–59	6.3 (13.2)	13.2 (12.0)	9.9 (29.6)
60–69	4.5 (7.8)	15.0 (13.6)	13.8 (23.0)
70 or more	4.7 (10.8)	15.9 (9.5)	3.2 (8.4)
p-value (bivariate)	0.731	0.728	0.538
<i>Adjusted p-value</i>	0.101	0.651	0.545
Cohabitation			
Alone	3.6 (7.4)	13.5 (10.6)	11.1 (13.6)
With a partner	4.8 (9.3)	15.1 (12.8)	10.5 (22.3)
Children over 18 years old	4.5 (12.6)	13.9 (8.0)	0.0 (0.0)
With other people	5.6 (14.8)	18.2 (12.8)	22.2 (0.0)
p-value (bivariate)	0.771	0.417	0.868
<i>Adjusted p-value</i>	0.110	0.998	0.287
Breast surgery			
Conservative	5.1 (9.4)	15.4 (12.8)	11.4 (21.8)
Radical	4.5 (9.5)	14.4 (11.2)	9.8 (21.4)
p-value (bivariate)	0.581	0.465	0.772
<i>Adjusted p-value</i>	0.146	0.941	0.404
Axillary surgery			
Axillary node dissection	5.3 (10.2)	15.2 (11.1)	3.7 (9.1)
Sentinel node biopsy	4.7 (9.0)	15.1 (12.6)	13.0 (23.7)
No	4.4 (9.4)	13.4 (14.9)	0.0 (0.0)
p-value (bivariate)	0.822	0.851	0.147
<i>Adjusted p-value</i>	0.127	0.957	0.261
Radiotherapy			
No	3.9 (6.9)	16.2 (13.4)	25.4 (34.4)
Yes	5.0 (9.8)	14.8 (12.0)	8.9 (19.0)
p-value (bivariate)	0.461	0.465	0.055
<i>Adjusted p-value</i>	0.169	0.975	0.275
Limiting comorbidity			
No	4.8 (8.8)	11.5 (10.3)	6.6 (16.1)
Yes	5.0 (10.2)	18.9 (13.1)	17.6 (27.2)
p-value (bivariate)	0.843	0.000	0.047
<i>Adjusted p-value</i>	0.141	0.752	0.299

Adjusted p-value: adjusting for years since beginning of treatment.

Supplementary table S3c. Group comparisons: QLQ-BR42 scales. Adjusted for time since beginning of treatment.

	Endocrine- related Symptoms	Skin toxicity / neuropathy	Weight gain	Musculo / Skeletal
Age at treatment				
< 55 years	6.1 (7.7)	11.3 (12.5)	14.7 (25.6)	26.0 (23.4)
55–59	10.3 (16.5)	17.5 (18.8)	19.5 (30.2)	34.5 (31.0)
60–69	8.4 (10.3)	15.3 (17.0)	21.3 (28.2)	33.7 (26.2)
70 or more	7.1 (11.5)	15.0 (14.9)	10.4 (24.4)	33.3 (22.9)
p-value (bivariate)	0.502	0.579	0.127	0.570
Adjusted p-value	0.624	0.445	0.574	0.102
Cohabitation				
Alone	6.2 (8.4)	13.3 (15.4)	13.8 (26.3)	34.6 (26.3)
With a partner	9.2 (12.8)	15.5 (16.7)	20.8 (28.6)	31.6 (26.2)
Children over 18 years old	7.6 (9.8)	11.9 (15.1)	28.6 (30.0)	34.5 (27.8)
With other people	8.6 (8.4)	22.0 (18.7)	9.5 (20.4)	35.1 (21.7)
p-value (bivariate)	0.355	0.304	0.151	0.860
Adjusted p-value	0.505	0.726	0.475	0.247
Breast surgery				
Conservative	9.1 (12.7)	13.6 (16.7)	18.6 (29.0)	32.3 (26.0)
Radical	6.9 (8.9)	17.0 (15.9)	17.5 (26.0)	33.7 (25.9)
p-value (bivariate)	0.136	0.129	0.767	0.691
Adjusted p-value	0.777	0.673	0.450	0.203
Axillary surgery				
Axillary node dissection	5.8 (6.5)	14.3 (14.8)	19.3 (28.4)	33.0 (24.2)
Sentinel node biopsy	9.2 (12.8)	15.6 (17.2)	17.9 (27.6)	32.2 (26.9)
No	13.3 (15.6)	13.3 (17.3)	6.7 (14.9)	50.0 (20.4)
p-value (bivariate)	0.056	0.819	0.608	0.322
Adjusted p-value	0.809	0.617	0.441	0.186
Radiotherapy				
No	8.7 (10.9)	18.7 (17.7)	15.2 (20.6)	29.8 (26.0)
Yes	8.1 (11.4)	14.6 (16.2)	18.8 (28.8)	33.5 (26.0)
p-value (bivariate)	0.785	0.183	0.489	0.455
Adjusted p-value	0.610	0.634	0.409	0.237
Limiting comorbidity				
No	6.8 (10.3)	9.6 (12.7)	12.5 (22.5)	25.3 (23.8)
Yes	9.7 (12.1)	21.5 (17.9)	24.7 (31.5)	41.7 (25.6)
p-value (bivariate)	0.049	0.000	0.001	0.000
Adjusted p-value	0.772	0.442	0.533	0.193

Adjusted p-value: adjusting for years since beginning of treatment.

Supplementary table S4. Group comparisons: QLQ-ELD14. Adjusted for time since beginning of treatment.

	Mobility	Worries about others	Future worries	Maintaining purpose	Burden of illness	Joint stiffness	Family support
Age at treatment							
< 55 years	10.3 (13.5)	28.0 (24.8)	19.2 (20.0)	85.0 (20.7)	9.8 (18.2)	28.5 (26.4)	83.7 (33.4)
55–59	16.3 (21.0)	38.1 (21.2)	24.9 (21.1)	68.5 (29.1)	6.3 (15.2)	34.1 (29.7)	83.7 (30.7)
60–69	17.9 (22.9)	35.2 (22.4)	27.1 (23.9)	64.2 (29.9)	8.7 (16.2)	39.3 (31.1)	75.9 (32.9)
70 or more	21.4 (20.1)	28.4 (19.9)	25.5 (23.1)	60.2 (29.3)	10.4 (19.9)	42.8 (27.7)	72.1 (32.1)
p-value (bivariate)	0.065	0.031	0.278	0.000	0.639	0.071	0.151
Adjusted p-value	0.011	0.248	0.552	0.002	0.133	0.765	0.040
Cohabitation							
Alone	17.4 (19.0)	31.8 (21.6)	25.2 (22.4)	61.0 (26.3)	8.4 (17.9)	35.3 (29.7)	65.9 (36.7)
With a partner	15.2 (22.2)	36.2 (22.5)	26.7 (24.1)	66.7 (30.7)	6.6 (14.0)	38.7 (30.2)	81.0 (29.8)
Children over 18 years old	31.3 (25.7)	43.9 (22.7)	41.4 (20.5)	43.9 (23.9)	10.6 (15.4)	48.5 (34.5)	51.5 (37.6)
With other people	21.7 (18.7)	14.3 (15.2)	21.2 (23.8)	64.3 (27.0)	7.9 (20.8)	49.2 (27.1)	71.4 (35.4)
p-value (bivariate)	0.066	0.000	0.124	0.059	0.755	0.186	0.001
Adjusted p-value	0.410	0.065	0.738	0.012	0.468	0.619	0.254
Breast surgery							
Conservative	18.4 (22.4)	33.1 (22.5)	26.2 (23.8)	66.8 (30.0)	9.2 (18.0)	36.1 (30.3)	75.4 (33.4)
Radical	15.8 (19.1)	33.6 (22.2)	24.4 (21.7)	66.1 (28.7)	8.1 (15.7)	40.7 (29.1)	79.9 (31.3)
p-value (bivariate)	0.294	0.837	0.502	0.834	0.572	0.190	0.228
Adjusted p-value	0.515	0.059	0.608	0.006	0.489	0.358	0.023
Axillary surgery							
Axillary node dissection	18.9 (19.1)	36.8 (24.0)	25.5 (22.2)	65.8 (27.0)	9.8 (16.9)	36.3 (29.7)	73.6 (36.5)
Sentinel node biopsy	16.3 (22.4)	31.4 (21.7)	25.5 (23.9)	66.8 (30.4)	7.5 (15.7)	39.5 (30.5)	79.1 (30.2)
No	20.3 (21.6)	30.4 (14.7)	24.8 (18.6)	67.6 (35.1)	17.6 (28.5)	33.3 (23.6)	78.4 (31.0)
p-value (bivariate)	0.499	0.111	0.993	0.948	0.050	0.549	0.366
Adjusted p-value	0.414	0.044	0.573	0.003	0.498	0.629	0.005
Radiotherapy							
No	13.5 (19.0)	29.7 (26.0)	21.5 (23.6)	73.9 (28.9)	5.8 (15.8)	37.0 (31.6)	80.4 (31.9)
Yes	18.1 (21.6)	33.6 (21.6)	26.1 (23.0)	65.2 (29.4)	9.4 (17.4)	38.2 (29.5)	76.9 (32.6)
p-value (bivariate)	0.181	0.270	0.210	0.062	0.186	0.788	0.491
Adjusted p-value	0.397	0.057	0.710	0.010	0.436	0.517	0.027
Limiting comorbidity							
No	12.2 (15.6)	30.5 (22.1)	19.9 (19.7)	72.0 (28.5)	7.5 (15.2)	30.0 (28.2)	78.0 (33.5)
Yes	23.5 (25.0)	36.4 (22.2)	32.0 (24.7)	60.5 (29.5)	10.6 (19.1)	47.1 (29.0)	76.3 (31.7)
p-value (bivariate)	0.000	0.018	0.000	0.001	0.107	0.000	0.642
Adjusted p-value	0.363	0.052	0.731	0.014	0.404	0.724	0.021

Adjusted p-value: adjusting for years since beginning of treatment.

Supplementary Table 5. Pre-post analysis

	1 st assessment. mean (SD)	2 nd assessment. mean (SD)	Change. mean (SD)	p-value
QLQ-C30				
Physical Functioning ^a	83.3 (16.9)	80.5 (18.1)	2.8 (8.6)	0.000
Role Functioning ^a	93.0 (14.8)	92.7 (15.1)	0.3 (5.3)	0.370
Emotional Functioning ^a	76.8 (20.6)	76.6 (20.1)	0.2 (8.2)	0.640
Cognitive Functioning ^a	89.1 (14.2)	88.0 (15.2)	1.0 (6.5)	0.005
Social Functioning ^a	96.9 (9.6)	96.5 (10.9)	0.4 (4.7)	0.103
Global Health Status ^a	75.5 (17.6)	74.0 (16.2)	1.6 (6.9)	0.000
Fatigue ^b	20.3 (20.3)	24.2 (19.5)	-3.8 (9.1)	0.000
Nausea ^b	1.2 (9.4)	1.4 (9.4)	-0.2 (5.3)	0.591
Pain ^b	21.2 (21.8)	22.2 (21.7)	-1.0 (9.1)	0.046
Dyspnoea ^b	8.4 (17.9)	8.2 (17.6)	0.2 (7.6)	0.618
Insomnia ^b	23.5 (28.6)	23.9 (28.5)	-0.4 (6.0)	0.206
Appetite loss ^b	4.7 (15.2)	5.1 (15.5)	-0.4 (7.1)	0.286
Constipation ^b	8.1 (19.5)	7.2 (18.1)	0.9 (8.9)	0.088
Diarrhoea ^b	2.3 (11.1)	2.0 (11.0)	0.3 (8.3)	0.492
Financial difficulties ^b	2.5 (14.7)	2.4 (14.1)	0.1 (1.9)	0.318
sum_score_C30 ^a	88.4 (9.5)	87.7 (9.7)	0.7 (3.3)	0.000
QLQ-BR42				
Body Image ^a	96.0 (13.2)	95.9 (13.2)	0.1 (5.7)	0.802
Sexual Function ^a	21.6 (15.4)	23.6 (15.1)	-2.0 (6.8)	0.004
Sexual Enjoyment ^a	44.6 (21.0)	44.6 (20.3)	0.0 (8.0)	1.000
Future Perspective ^a	76.0 (26.1)	75.1 (27.0)	0.9 (12.4)	0.218
Breast Satisfaction ^a	76.7 (25.6)	77.0 (25.1)	-0.2 (4.6)	0.468
Arm Symptoms	9.2 (14.7)	9.3 (14.0)	-0.1 (5.8)	0.826
Breast Symptoms	4.7 (9.2)	5.4 (10.2)	-0.7 (5.9)	0.044
Upset by loss hair	30.0 (30.3)	32.1 (31.1)	-2.1 (18.6)	0.320
Systemic Chemotherapy Side Effects	14.7 (12.2)	15.5 (13.7)	-0.8 (7.0)	0.052
Vaginal Symptoms	9.8 (21.9)	8.2 (16.9)	1.5 (8.2)	0.159
Endocrine-related Symptoms	8.0 (11.2)	8.6 (12.2)	-0.6 (4.6)	0.054
Skin toxicity / neuropathy	14.9 (16.0)	15.4 (16.3)	-0.5 (4.3)	0.091
Weight gain	17.7 (27.1)	17.7 (26.5)	0.0 (5.5)	1.000
Musculo / Skeletal	32.5 (25.7)	33.1 (25.3)	-0.6 (6.0)	0.159
QLQ-ELD14				
Mobility ^b	16.4 (20.4)	16.5 (20.4)	-0.1 (3.7)	0.602
Worries about others ^b	33.2 (22.5)	33.9 (23.1)	-0.7 (7.0)	0.103
Future worries ^b	24.7 (22.6)	25.0 (22.7)	-0.3 (4.8)	0.234
Maintaining purpose ^a	67.1 (29.3)	66.6 (29.1)	0.5 (7.7)	0.265
Burden of illness ^b	8.7 (17.2)	9.4 (18.5)	-0.6 (8.7)	0.228
Joint stiffness ^b	37.3 (29.8)	38.2 (30.4)	-0.9 (7.6)	0.045
Family support ^a	77.2 (32.8)	76.8 (32.6)	0.4 (8.6)	0.372

a The scores range from 0 to 100, where a higher score represents a higher functional level.

b The scores range from 0 to 100, where a higher score represents more severe symptoms.